NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3)

Post Date

January 16th 2015

Application Due Date

April 15th 2015

Funding Opportunity Number

RFA-DA-15-017

CFDA Number(s)

93.279

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Education
Health

Number of Awards

3

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $3000000

• Award Range:

  $None - $1000000

Grant Description

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. The UH2/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases.The UH2 is to support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UH2.UH2 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UH2 and UH3 phases. Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-017.html